Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omalizumab biosimilar - CuraTeQ Biologics

Next Previous
X
Search
Drug Profile

Omalizumab biosimilar - CuraTeQ Biologics

Alternative Names: Anti-IgE monoclonal antibody E25 - CuraTeQ Biologics; BP-11; rhuMAb-E25

Latest Information Update: 10 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CURATEQ BIOLOGICS PRIVATE LIMITED
  • Class Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action IgE receptor antagonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Chronic urticaria

Most Recent Events

  • 04 Apr 2024 efficacy, adverse events, pharmacodynamics and immunognicity data from a phase I trial in Chronic urticaria released by CuraTeQ Biologics
  • 16 Nov 2023 Syneos Health completes a phase I trial in Chronic-urticaria (In volunteers) in Australia and New Zealand (SC) (NCT05053334)
  • 02 Feb 2023 Phase-III clinical trials in Chronic-urticaria in Lithuania (SC) (EudraCT2022-001745-20)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top